Miguel-Angel Perales, MD, and Caron A. Jacobson, MD, share insights regarding the context and implications of the recent actions by the FDA to add boxed warnings to CAR T-cell therapies.
Ongoing Research Aims to Expand Treatment Options, Address Unmet Needs in GVHD
Revisit the OncLive On Air Episodes From February 2024
AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma
SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC